Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MILES-4: Pemetrexed vs Gemcitabine +/- Cisplatin in Elderly NSCLC
NCT01656551Phase 3
Key facts
- Status
- Unknown
- Start
- Aug 2012
- Primary completion
- Nov 2024
- Countries
- 1
- Sponsor
- National Cancer Institute
- Modality
- Small Molecules
- Drugs
- cisplatinpemetrexed
- Conditions
- Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
01
Overview
Phase 3, randomised, open-label trial of cisplatin and pemetrexed in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by National Cancer Institute. Status: unknown.
02
Design
- Study design
- RandomizedOpen-label
03
Registry description
The purposes of this study are to test whether the addition of cisplatin to single agent chemotherapy (either gemcitabine or pemetrexed) prolongs survival in elderly patients with non squamous non small cell lung cancer (NSCLC), and to test whether pemetrexed prolongs survival as compared to gemcitabine in elderly patients with non squamous NSCLC.
Beyond the preview
Go deeper on NCT01656551.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01656551.